FreeTheAI

DocMorris Hits Q3 Profitability Breakeven Early and Raises Full-Year 2026 Outlook

BullishMedium impact
DOCMCHF 14.00 4.55%

DocMorris AG (BX:DOCM) reported a 21.5% year-on-year increase in third-quarter external revenue to CHF 342.7 million, driven by a 78.3% surge in prescription medicine sales. The online pharmacy and healthcare company generated an adjusted EBITDA of CHF 0.6 million for the period, reaching its quarterly profitability breakeven milestone earlier than planned.

The quarter marked a significant operational acceleration for the business, expanding its active customer base to 13.1 million. Digital services revenue jumped 46.1% to CHF 13.9 million, while overall nine-month external revenue rose 15.5% to CHF 970.6 million. Refinancing actions in September 2026 also extended the company's debt maturity profile into 2031 at lower relative borrowing costs.

Following these results, management increased its full-year 2026 financial forecast. DocMorris now projects full-year external revenue growth between 12.5% and 15%, up from its previous range of 9% to 13%, with adjusted EBITDA expected to be better than negative CHF 10 million. The company reiterated its goal of achieving free cash flow breakeven during 2027.

Key points

  • Q3 external revenue rose 21.5% year-on-year to CHF 342.7 million, led by a 78.3% increase in prescription medicine sales.
  • Adjusted EBITDA reached CHF 0.6 million in Q3, achieving profitability breakeven ahead of schedule.
  • Active customers reached 13.1 million after adding 0.2 million new users during the third quarter.
  • Full-year 2026 external revenue growth forecast was raised to between 12.5% and 15%.
  • Management reaffirmed its target to achieve free cash flow breakeven in 2027.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were DocMorris's Q3 2026 revenue and earnings results?

DocMorris reported Q3 external revenue of CHF 342.7 million, up 21.5% year-on-year. The company achieved an adjusted EBITDA of CHF 0.6 million, hitting its quarterly breakeven target ahead of schedule.

Why did DocMorris raise its 2026 financial guidance?

The company upgraded its outlook due to strong momentum in prescription sales, which grew 78.3% in Q3, alongside improvements in operational efficiency and growth in digital services.

What is DocMorris's updated guidance for full-year 2026?

DocMorris expects full-year external revenue growth of 12.5% to 15% and adjusted EBITDA better than negative CHF 10 million, with capital expenditure remaining below CHF 30 million.